Exploration of Marine Bioactive Compounds Against Alzheimer’s Disease: An in Silico Molecular Docking Approach Targeting Human Acetylcholinesterase

Alzheimer's disease (AD) is a progressive neurological disorder characterized by gradual cognitive decline and memory loss. A reduction in acetylcholine levels in the head region is one of its most important pathological signs. This is mostly caused by acetylcholinesterase (AChE) being more active. Current therapeutic agents offer merely symptomatic relief and are frequently accompanied by adverse effects. Therefore, there is vital requirement to explore safer and more effective alternatives. Marine bioactive compounds have emerged as promising candidates due to their structural diversity and pharmacological potential. This study aims to evaluate the inhibitory potential of selected marine -derived bioactive compounds against human AChE using an in silico molecular docking approach. The docking results revealed that several marine compounds exhibited strong binding affinities, in some cases outperforming standard synthetic drugs. These results underscore the promise of marine-derived metabolites as safer and more efficacious alternatives to synthetic agents for the treatment of Alzheimer’s disease.